Direct-acting antivirals and chronic hepatitis C: towards elimination

Abstract

Hepatitis C virus (HCV) is a major cause of liver morbidity and mortality worldwide with increasing disease burden projected for the next several decades. The timely advent of direct-acting antivirals (DAAs) sparked significant public health responses aimed at HCV elimination by 2030. This review will focus on the implications of the DAAs in terms of medical progress, barriers to HCV elimination as a public health threat, and current gaps that will require further innovation. We utilized PubMed searches with the relevant keywords for articles published in the last 5 years, as well as personal collections of relevant publications. DAAs have proven to be safe and effective. DAAs are well suited for nearly all infected patients, and many countries worldwide have taken on initial treatment scale-up strategies. These unprecedented efforts, albeit significant, face extraordinary challenges related to the high infection burden, stigma, and financial constraints. Currently, few countries are progressing towards HCV elimination, as this attainable public health goal requires explicit, adequately resourced, and coordinated public health prioritization at all levels.

Keywords

Direct-acting antivirals / hepatitis surveillance / hepatitis C elimination

References

[1] Polaris Observatory HCV CollaboratorsGlobal prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study..Lancet Gastroenterol Hepatol2017;2:161-76

[2] Gower E,Blach S,Razavi H.Global epidemiology and genotype distribution of the hepatitis C virus infection..J Hepatol2014;61:S45-57

[3] Stanaway JD,Naghavi M,Vos T.The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013..Lancet2016;388:1081-8 PMCID:PMC5100695

[4] Bukh J,Purcell RH.Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes..Semin Liver Dis1995;15:41-63

[5] Freeman AJ,Ffrench RA.Immunopathogenesis of hepatitis C virus infection..Immunol Cell Biol2001;79:515-36

[6] Maylin S,Moucari R,Ripault MP.Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C..Gastroenterology2008;135:821-9

[7] Grebely J,Hellard M,Osburn WO.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine..Lancet Infect Dis2012;12:408-14 PMCID:PMC3608418

[8] Afdhal NH,Schooley RT,Ward JW.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices..J Viral Hepat2013;20:745-60 PMCID:PMC3886291

[9] WHO. Global health sector strategies on viral hepatitis 2016-2021. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. [Last accessed on 28 Nov 2018]

[10] Lok AS,Lawitz E,Everson GT.Preliminary study of two antiviral agents for hepatitis C genotype 1..N Engl J Med2012;366:216-24

[11] Choo QL,Weiner AJ,Bradley DW.Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome..Science1989;244:359-62

[12] Major ME.The molecular virology of hepatitis C..Hepatology1997;25:1527-38

[13] Lohmann V,Koch J,Theilmann L.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line..Science1999;285:110-3

[14] Götte M.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights..Nat Rev Gastroenterol Hepatol2016;13:338-51

[15] Wyles DL,Sulkowski MS,Luetkemeyer A.Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1..N Engl J Med2015;373:714-25

[16] Rockstroh JK,Katlama C,Mallolas J.Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial..Lancet HIV2015;2:e319-27

[17] Rockstroh JK,Viani RM,Wyles D.Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study..Clin Infect Dis2018;67:1010-7 PMCID:PMC6137115

[18] Osinusi A,Kohli A,Seamon C.Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection..JAMA2015;313:1232-9

[19] Naggie S,Saag M,Ruane P.Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1..N Engl J Med2015;373:705-13 PMCID:PMC4892372

[20] Sulkowski MS,Wyles D,Lalezari J.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial..JAMA2015;313:1223-31

[21] Lawitz E,Ghalib R,Younossi ZM.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study..Lancet2014;384:1756-65

[22] AASLD/IDSA. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study abstract PS104. Available from: https://www.hcvguidelines.org/references/wyles-2016. [Last accessed on 28 Nov 2018]

[23] Charlton M,Flamm SL,Landis C.Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease..Gastroenterology2015;149:649-59

[24] Manns M,Gane EJ,McCaughan G.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial..Lancet Infect Dis2016;16:685-97

[25] Bourlière M,de Ledinghen V,Zoulim F.Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)..Lancet Infect Dis2015;15:397-404

[26] Curry MP,Bzowej N,Korenblat KM.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis..N Engl J Med2015;373:2618-28

[27] Feld JJ,Hézode C,Ruane PJ.Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection..N Engl J Med2015;373:2599-607

[28] Poordad F,Vierling JM,Fontana RJ.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence..Hepatology2016;63:1493-505 PMCID:PMC5069651

[29] Reau N,Rhee S,Agarwal K.MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection..Hepatology2017;66:S90-1

[30] Charlton M,Flamm SL,Landis C.Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease..Gastroenterology2015;149:649-59

[31] Agarwal K,Müllhaupt B,McNabb B.Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients..J Hepatol2018;69:603-7

[32] Fontana RJ,Moreno-Zamora A,Joshi S.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection..Liver Transpl2016;22:446-58

[33] O’Leary JG,Brown K,Firpi-Morell R.Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study..Transpl Int2017;30:196-208

[34] Roth D,Bruchfeld A,Silva M.Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study..Lancet2015;386:1537-45

[35] Gane Ed,Pugatch D,Bräu N.EXPEDITION-4: efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection..Hepatology2016;64:1125A

[36] Colombo M,Liu H,Dvory-Sobol H.Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial..Ann Intern Med2017;166:109-17

[37] Sawinski D,Ajeti A,Lim M.Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents..Am J Transplant2016;16:1588-95

[38] Goetsch MR,Varshney M,Overton ET.Direct-acting antivirals in kidney transplant patients: successful hepatitis C treatment and short-term reduction in urinary protein/creatinine ratios..Pathog Immun.2017;2:366-75 PMCID:PMC5654569

[39] Balistreri WF,Rosenthal P,Lin CH.The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection..Hepatology2017;66:371-8

[40] Wirth S,Gonzalez-Peralta RP,Balistreri WF.Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection..Hepatology2017;66:1102-10

[41] CROI. Retreatment of HCV/HIV-coinfected patients who failed 12 weeks of LDV/SOF. Available from: www.croiconference.org/sessions/retreatment-hcvhiv-coinfected-patients-who-failed-12-weeks-ldvsof. [Last accessed on 28 Nov 2018]

[42] EASL. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: results of the retreatment study. Available from: http://www.natap.org/2016/EASL/EASL_11.htm. [Last accessed on 28 Nov 2018]

[43] Bourlière M,Flamm SL,Ramji A.Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection..N Engl J Med2017;376:2134-46

[44] AASLD/IDSA. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [Abstract 253]. Available from: https://www.hcvguidelines.org/references/zeuzem-2016. [Last accessed on 28 Nov 2018]

[45] Poordad F,Asatryan A,Reindollar RW.Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment..Hepatology2017;66:389-97 PMCID:PMC5573922

[46] Poordad F,Asatryan A,Shaw DR.MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure..Gastroenterology2017;152:S1057

[47] Rice CM.Hepatitis C: treatment triumphs..Nature2014;510:43-4

[48] Poynard T,Manns M,Lindsay K.Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C..Gastroenterology2002;122:1303-13

[49] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[50] van der Meer AJ,Feld JJ,Dufour JF.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis..JAMA2012;308:2584-93

[51] Veldt BJ,Wedemeyer H,Hofmann WP.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis..Ann Intern Med2007;147:677-84

[52] Johnson RJ,Couser WG,Wilson J.Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy..Kidney Int1994;46:1700-4

[53] Arase Y,Suzuki Y,Kobayashi M.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C..Hepatology2009;49:739-44

[54] Takikawa H,Shoji S,Yamanaka M.Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda..J Hepatol1995;22:249-50

[55] Ghany MG,Thomas DL.Diagnosis, management, and treatment of hepatitis C: an update..Hepatology2009;49:1335-74

[56] Jézéquel C,Desille Y,Lainé F.Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up..J Hepatol2015;62:S589

[57] Øvrehus ALH,Christensen PB,Weis N.Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years..J Hepatol2015;62:S591-2

[58] CROI. Impact of deferring HCV treatment on liver-related events in HIV+ patients. Available from: http://www.croiconference.org/sessions/impact-deferring-hcv-treatment-liver-related-events-hiv-patients. [Last accessed on 28 Nov 2018]

[59] Gerber L,Stepanova M,Weinstein A.Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection..Clin Gastroenterol Hepatol.2016;14:15-64

[60] Younossi ZM,Smith NJ,Beckerman R.Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States..Hepatology2015;61:1471-8

[61] Younossi ZM,Sulkowski M,Puoti M.Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes..J Infect Dis2015;212:367-77 PMCID:PMC5007583

[62] Bonkovsky HL,Malet PF,Fontana RJ.Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis..J Hepatol2007;46:420-31 PMCID:PMC1995129

[63] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[64] ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts)Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[65] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[66] Backus LI,Shahoumian TA.Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease..Hepatology2017;

[67] Grebely J,Taylor LE.Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels..J Infect Dis2013;207:S19-25 PMCID:PMC3565594

[68] Harris M.Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors..Harm Reduct J2013;10:7 PMCID:PMC3686576

[69] Wolfe D,Harris M,Albers E.Human rights and access to hepatitis C treatment for people who inject drugs..Int J Drug Policy2015;26:1072-80

[70] Aspinall EJ,Doyle JS,Hutchinson SJ.Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis..Clin Infect Dis2013;57:S80-9

[71] Dore GJ,Litwin AH,Gane EJ.Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial..Ann Intern Med2016;165:625-34

[72] Feld JJ,Coakley E,Nelson DR.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin..N Engl J Med2014;370:1594-603

[73] Grebely J,Zeuzem S,Fox R.Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis c virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials..Clin Infect Dis2016;63:1479-81 PMCID:PMC5106608

[74] Grebely J,Wedemeyer H,Sulkowski MS.Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials..J Hepatol2017;66:S514

[75] Grebely J,Brown A,Puoti M.Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials..Clin Infect Dis2016;63:1405-11

[76] Read P,Chronister K,Kearley J.Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting..Int J Drug Policy2017;47:209-15

[77] Mason K,Guyton M,Lettner B.Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada..Int J Drug Policy2017;47:202-8

[78] Mazhnaya A,Barnard T,Filippovych S.Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: an evaluation of programmatic and treatment outcomes..Int J Drug Policy2017;47:187-95 PMCID:PMC5918282

[79] Norton BL,Bachhuber MA,DeLuca J.High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic..Int J Drug Policy2017;47:196-201 PMCID:PMC5822435

[80] Boglione L,De Nicolò A,Cariti G.Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study..J Viral Hepat2017;24:850-7

[81] Grebely J,Conway B,Bruggmann P.Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study..J Hepatol2017;66:S513

[82] Martin NK,Foster GR,Goldberg DJ.Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility..J Hepatol2011;54:1137-44

[83] Martin NK,Hutchinson SJ,Vickerman P.Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy..Clin Infect Dis2013;57:S39-45 PMCID:PMC3722076

[84] WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf. [Last accessed on 28 Nov 2018]

[85] AASLD/IDSA. HCV guidance: recommendations for testing, managing and treating hepatitis C. Available from: http://www.hcvguidelines.org. [Last accessed on 28 Nov 2018]

[86] EASL. Recommendations on treatment of hepatitis C. Available from: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf. [Last accessed on 28 Nov 2018]

[87] Grebely J,Bruggmann P,Backmund M.Recommendations for the management of hepatitis C virus infection among people who inject drugs..Intl J Drug Policy2015;26:1028-38 PMCID:PMC6130980

[88] EASL. Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in an Italian cohort. Available from: https://medicalxpress.com/news/2018-04-sustained-virological-response-oral-hepatitis.html. [Last accessed on 28 Nov 2018]

[89] Infohep. Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe. Available from: www.infohep.org/Direct-acting-antivirals-bring-fewer-HCV-related-liver-transplants-better-survival-after-transplantation-in-Europe/page/3257600/. [Last accessed on 28 Nov 2018]

[90] Stanaway JD,Naghavi M,Vos T.The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013..Lancet2016;388:1081-8 PMCID:PMC5100695

[91] Konerman MA.Hepatitis c treatment and barriers to eradication..Clin Transl Gastroenterol2016;7:e193 PMCID:PMC5288596

[92] Mugavero MJ,Horn T.The state of engagement in HIV care in the United States: from cascade to continuum to control..Clin Infect Dis2013;57:1164-71

[93] Holmberg SD,Moorman AC.Hepatitis C in the United States..N Engl J Med2013;368:1859-61 PMCID:PMC5672915

[94] Stein JA,Robertson M.Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen behavioral model for vulnerable populations..Health Psychol2012;31:20-30 PMCID:PMC3235541

[95] Desai RA,Agnello V.Prevalence of hepatitis C virus infection in a sample of homeless veterans..Soc Psychiatry Psychiatr Epidemiol2003;38:396-401

[96] Nyamathi AM,Robbins W,Wiley D.Risk factors for hepatitis C virus infection among homeless adults..J Gen Intern Med2002;17:134-43 PMCID:PMC1495011

[97] Stein JA.Correlates of hepatitis C virus infection in homeless men: a latent variable approach..Drug Alcohol Depend2004;75:89-95

[98] Marinho RT.Hepatitis C, stigma and cure..World J Gastroenterol2013;19:6703-9 PMCID:PMC3812468

[99] Grundy G.Understanding social stigma in women with hepatitis C..Nurs Stand2004;19:35-9

[100] Paterson BL,Hirsch G.The depiction of stigmatization in research about hepatitis C..Int J Drug Policy2007;18:364-73

[101] Schäfer M,Laakmann G.Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C..Addiction2000;95:1101-4

[102] Bogart LM,Kennedy D,Murphy DA.HIV-related stigma among people with HIV and their families: a qualitative analysis..AIDS Behav2008;12:244-54

[103] Butt G.Stigma in the context of hepatitis C: concept analysis..J Adv Nurs2008;62:712-24

[104] Zickmund S,Masuda M,LaBrecque DR.“They treated me like a leper”. Stigmatization and the quality of life of patients with hepatitis C..J Gen Intern Med2003;18:835-44 PMCID:PMC1494932

[105] Dowsett LE,Lorenzetti DL,Clement F.Living with hepatitis C virus: a systematic review and narrative synthesis of qualitative literature..Can J Gastroenterol Hepatol2017;2017:3268650 PMCID:PMC5424189

[106] Nelson PK,Cowie B,Des Jarlais D.Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews..Lancet2011;378:571-83 PMCID:PMC3285467

[107] Hajarizadeh B,Dore GJ.Epidemiology and natural history of HCV infection..Nat Rev Gastroenterol Hepatol2013;10:553-62

[108] Hagan H,Des Jarlais DC.Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place..Am J Epidemiol2008;168:1099-109 PMCID:PMC2727245

[109] Morris MD,Bruneau J,Hellard M.Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration..Clin Infect Dis2017;64:860-9 PMCID:PMC5439493

[110] Page K,Hahn JA,Prins M.Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention..Clin Infect Dis2013;57:S32-8 PMCID:PMC3722077

[111] Wiessing L,Grady B,Sperle I.Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention..PLoS One2014;9:e103345 PMCID:PMC4113410

[112] Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Eliminating+the+public+health+problem+of+hepatitis+B+and+C+in+the+United+States%3A+phase+one+report. [Last accessed on 28 Nov 2018]

[113] Zibbell JE,Patel RC,Sanders KJ.Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012..MMWR Morb Mortal Wkly Rep2015;64:453-8 PMCID:PMC4584548

[114] Suryaprasad AG,Xu F,Hamilton J.Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012..Clin Infect Dis2014;59:1411-9

[115] Van Handel MM,Hallisey EJ,Zibbell JE.County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States..J Acquir Immune Defic Syndr2016;73:323-31 PMCID:PMC5479631

[116] Harris AM,Schillie S,Kainer MA.Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and West Virginia, 2006-2013..MMWR Morb Mortal Wkly Rep2016;65:47-50

[117] Iversen J,Catlett B,Dore GJ.Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia..Int J Drug Policy2017;47:77-85

[118] Butler K,Sutherland R,Breen C.Hepatitis C testing in general practice settings: a cross-sectional study of people who inject drugs in Australia..Int J Drug Policy2017;47:102-6

[119] van Santen DK,Lindenburg K,Prins M.HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam cohort studies, 1985-2015..Int J Drug Policy2017;47:95-101

[120] Chan DP,Wong HT,Hung CC.Sexually acquired hepatitis C virus infection: a review..Int J Infect Dis2016;49:47-58

[121] Ingiliz P,Rodger A,Mauss S.HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe..J Hepatol2017;66:282-7

[122] Salazar-Vizcaya L,Zahnd C,Battegay M.Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions..Hepatology2016;64:1856-69 PMCID:PMC5132019

[123] Dore GJ.Hepatitis C treatment as prevention among HIV infected men who have sex with men: feasible?.Hepatology2016;64:1834-6

[124] Martin TC,McClure M.HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach..Hepatology2015;61:1437

[125] Hagan H,Neurer J.Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men..AIDS2015;29:2335-45 PMCID:PMC4640945

[126] Abravanel F,Chauveau M,Izopet J.Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men..Clin Infect Dis2016;63:1271-2

[127] Pineda JA,Téllez F,García F.Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C..J Infect2015;71:571-7

[128] Young J,Gill J,Cooper C.Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV..Clin Infect Dis2017;64:1154-62 PMCID:PMC5399935

[129] Dore GJ,Litwin AH,Gane EJ.Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial..Ann Intern Med2016;165:625-34

[130] Midgard H,Mæland A,Kileng H.Hepatitis C reinfection after sustained virological response..J Hepatol2016;64:1020-6

[131] Thomas DL,Rai RM,Schaeffer M.The natural history of hepatitis C virus infection: host, viral, and environmental factors..JAMA2000;284:450-6

[132] Mehta SH,Hoover DR,Mao Q.Protection against persistence of hepatitis C..Lancet2002;359:1478-83

[133] Larney S,Beckwith CG,Jarlais DD.Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis..Hepatology2013;58:1215-24 PMCID:PMC3723697

[134] UNSW. National prison entrants’ bloodborne virus and risk behaviour survey report 2004, 2007, 2010, and 2013 . Available from: https://kirby.unsw.edu.au/report/national-prison-entrants-bloodborne-virus-and-risk-behaviour-survey-report-2004-2007-2010-and. [Last accessed on 28 Nov 2018]

[135] Zampino R,Sagnelli C,Sagnelli E.Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment..World J Hepatol2015;7:2323-30 PMCID:PMC4577639

[136] Walmsley R.World prison population list.2016;11th ed.Birckbeck University of London: Institute for Criminal Policy Research

[137] United Nations. 45/111. Basic principles for the treatment of prisoners. Available from: http://www.un.org/documents/ga/res/45/a45r111.htm. [Last accessed on 28 Nov 2018]

[138] Bretschneider W.Expert perspectives on Western European prison health services: do ageing prisoners receive equivalent care?.J Bioeth Inq2014;11:319-32

[139] de Viggiani N.Unhealthy prisons: exploring structural determinants of prison health..Sociol Health Illn2007;29:115-35

[140] Teutsch S,Scheuer N,Hosseiny P.Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort..BMC Public Health2010;10:633 PMCID:PMC2975656

[141] Dolan K,Scheuer N,Rawlinson W.Incidence and risk for acute hepatitis C infection during imprisonment in Australia..Eur J Epidemiol2010;25:143-8

[142] Skipper C,Parkes J,Rosenberg WM.Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy..Gut2003;52:1500-4 PMCID:PMC1773842

[143] Spaulding AC,Lau DT,Seeff LB.A framework for management of hepatitis C in prisons..Ann Intern Med2006;144:762-9

[144] Yap L,Thompson S,Jones J.A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners..PLoS One2014;9:e87564 PMCID:PMC3937313

[145] Lloyd AR,Lange J,Post JJ.Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting..Clin Infect Dis2013;56:1078-84

[146] Fazel S.The health of prisoners..Lancet2011;377:956-65

[147] Spaulding AC,Seals RM,Kavasery R.Diversity of release patterns for jail detainees: implications for public health interventions..Am J Public Health2011;101:S347-52 PMCID:PMC3222492

[148] McGowan CE.Barriers to hepatitis C treatment..Liver Int2012;32:151-6 PMCID:PMC3955982

[149] Zickmund SL,Bielefeldt K.A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease?.Dig Dis Sci2007;52:2550-6

[150] Shehab TM,Lok AS.Management of hepatitis C patients by primary care physicians in the USA: results of a national survey..J Viral Hepat2001;8:377-83

[151] Kanwal F,Spiegel BM,Dominitz JA.Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors..Hepatology2007;46:1741-9

[152] Stoové MA,Dore GJ.The impact of injecting drug use status on hepatitis C-related referral and treatment..Drug Alcohol Depend2005;77:81-6

[153] Volk ML.Antiviral therapy for hepatitis C: why are so few patients being treated?.J Antimicrob Chemother2010;65:1327-9

[154] Iyengar S,Vogler S,Wiktor S.Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis..PLoS Med2016;13:e1002032 PMCID:PMC4886962

[155] Saag MS.Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL..Clin Infect Dis2015;61:169-70

[156] US Senate Committee on Finance. The Price of Sovaldi and its impact on the U.S. Health Care System. Available from: https://www.finance.senate.gov/imo/media/doc/2%20Introduction,%20Hepatitis%20C%20Background,%20Development%20of%20Sovaldi%20and%20Gilead’s%20Acquistion%20of%20Pharmasset%20(Introduction,%20Sections%201&2).pdf. [Last accessed on 28 Nov 2018]

[157] WHO. Global report on access to hepatitis C treatment. Focus on overcoming barriers. Available from: http://apps.who.int/iris/handle/10665/250625. [Last accessed on 28 Nov 2018]

[158] Morgan JR,Easterbrook P.Economic evaluation of HCV testing approaches in low and middle income countries..BMC Infect Dis2017;17:697 PMCID:PMC5688403

[159] WHO. Guidelines on hepatitis B and C testing. Available from: http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/. [Last accessed on 28 Nov 2018]

[160] Stein K,Walker A,Round A.Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis..J Hepatol2003;39:814-25

[161] Coffin PO,Golden MR.Cost-effectiveness and population outcomes of general population screening for hepatitis C..Clin Infect Dis2012;54:1259-71 PMCID:PMC3404694

[162] Wong WW,Feld JJ,Krahn M.Cost-effectiveness of screening for hepatitis C in Canada..CMAJ2015;187:E110-21 PMCID:PMC4330166

[163] Goel A,Chhatwal J.Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment..J Gastroenterol Hepatol2018;

[164] Peeling RW,Marinucci F.The future of viral hepatitis testing: innovations in testing technologies and approaches..BMC Infect Dis2017;17:699 PMCID:PMC5688478

[165] Dore GJ,Thursz M.Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)..J Viral Hepat2014;21:1-4

[166] Bruggmann P,Øvrehus AL,Brandão Mello CE.Historical epidemiology of hepatitis C virus (HCV) in selected countries..J Viral Hepat2014;21:5-33

[167] Chen DS,Mustapha B,Nersesov A.Strategies to manage hepatitis C virus infection disease burden-Volume 4..J Viral Hepat2017;24:44-63

[168] Denniston MM,Drobeniuc J,Ward JW.Chronic hepatitis C virus infection in the United States, National health and nutrition examination survey 2003 to 2010..Ann Intern Med2014;160:293-300 PMCID:PMC4562398

[169] Razavi H,Sarrazin C,Idilman R.The present and future disease burden of hepatitis c virus (HCV) infection with today’s treatment paradigm..J Viral Hepat2014;21:34-59

[170] Hepatitis B and C Public Policy Association ASBL. Hepatitis C elimination in Europe - European policy guidelines. Available from: http://www.hcvbrusselssummit.eu/images/documents/reports/HCV-Elimination-PolicyGuidelines.pdf. [Last accessed on 28 Nov 2018]

[171] Arora S,Murata G,Kalishman S.Outcomes of treatment for hepatitis C virus infection by primary care providers..N Engl J Med2011;364:2199-207 PMCID:PMC3820419

[172] Hill WD,Alvarez M.Capacity enhancement of hepatitis C virus treatment through integrated, community-based care..Can J Gastroenterol2008;22:27-32 PMCID:PMC2659116

[173] Lloyd AR,Lange J,Post JJ.Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting..Clin Infect Dis2013;56:1078-84

[174] Hill WD,Alvarez M.Capacity enhancement of hepatitis C virus treatment through integrated, community-based care..Can J Gastroenterol2008;22:27-32 PMCID:PMC2659116

[175] Nazareth S,Muwanwella N,Leembruggen N.Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth..J Telemed Telecare2013;19:101-6

[176] Beste LA,Ho PM,Kirsh SR.Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the department of veterans affairs..Am J Med2017;130:432-8

[177] Kattakuzhy S,Emmanuel B,Jenkins V.Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial..Ann Intern Med2017;167:311-8 PMCID:PMC5736381

[178] Mera J,Hariri S,Drevets DA.Identification and clinical management of persons with chronic hepatitis C virus infection - Cherokee Nation, 2012-2015..MMWR Morb Mortal Wkly Rep2016;65:461-6

[179] Hellard M,Doyle J.Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks..J Epidemiol Community Health2016;70:1151-4

[180] Centers for Disease Control and Prevention (CDC). Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6105a1.htm. [Last accessed on 28 Nov 2018]

[181] Scott N,GottfreÐsson M,Rúnarsdóttir V.Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020..J Hepatol2018;68:932-9

[182] European Union HCV CollaboratorsHepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study..Lancet Gastroenterol Hepatol2017;2:325-36

[183] Dore GJ.Elimination of hepatitis C virus in Australia: laying the foundation..Infect Dis Clin North Am2018;32:269-79

[184] National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and CStrom BL.Modeling the Elimination of Hepatitis C in the United States..A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report.2017;Washington (DC)National Academies Press (US)

[185] Suryaprasad AG,Xu F,Hamilton J.Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012..Clin Infect Dis2014;59:1411-9

[186] Holmberg SD,Moorman AC.Hepatitis C in the United States..N Engl J Med2013;368:1859-61 PMCID:PMC5672915

[187] Belperio PS,Gonzalez RI,Ross DB.Hepatitis C care in the department of veterans affairs: building a foundation for success..Infect Dis Clin North Am2018;32:281-92

[188] HHS.gov. The community response to viral hepatitis - contributions towards achieving the goals of the viral hepatitis action plan. Available from: https://www.hhs.gov/hepatitis/action-plan/viral-hepatitis-community-action/community-response-to-viral-hepatitis/index.html. [Last accessed on 29 Nov 2018]

[189] Waked I,El-Sayed MH,Razavi H.The current and future disease burden of chronic Hepatitis C virus infection in Egypt..Arab J Gastroenterol2014;15:45-52

[190] The World Bank. Treatment program policy analysis 2017 (English). Available from: http://documents.worldbank.org/curated/en/335981517329520478/Treatment-program-policy-analysis-2017. [Last accessed on 28 Nov 2018]

[191] The World Bank. Eliminating hepatitis C from Egypt: 2017 update on current trends and policyrecommendations - policy brief (English). Available from: http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-C-from-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief. [Last accessed on 28 Nov 2018]

[192] Mitruka K,Butsashvili M,Sabelashvili P.Launch of a nationwide hepatitis C elimination program - Georgia, April 2015..MMWR Morb Mortal Wkly Rep2015;64:753-7 PMCID:PMC4584859

[193] Gvinjilia L,Sergeenko D,Kamkamidze G.National progress toward hepatitis C elimination - Georgia, 2015-2016..MMWR Morb Mortal Wkly Rep2016;65:1132-5

[194] Nasrullah M,Gvinjilia L,Tsertsvadze T.The role of screening and treatment in national progress toward hepatitis C elimination - Georgia, 2015-2016..MMWR Morb Mortal Wkly Rep2017;66:773-6 PMCID:PMC5657814

[195] WHO. Brazil sets out path to eliminate hepatitis C by 2030. Available from: http://www.worldhepatitissummit.org/docs/default-source/press-releases/government-of-brazil/brazil-sets-out-path-to-eliminate-hepatitis-c-by-2030.pdf?sfvrsn=2. [Last accessed on 28 Nov 2018]

[196] Leidner AJ,Xu F,Spradling PR.Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease..Hepatology2015;61:1860-9 PMCID:PMC5802336

[197] Harris RJ,Rand E,Mutimer D.New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England..J Viral Hepat2016;23:631-43 PMCID:PMC4982023

[198] Martin NK,Dore GJ,Miners A.Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation..J Hepatol2016;65:17-25 PMCID:PMC4914770

[199] Hickman M,Huxtable R.Hepatitis C virus prevention and treatment prioritization - ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs..Addiction2017;112:201-3 PMCID:PMC5233591

[200] Lazarus JV,Harris M,Hetherington KL.Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017..J Int AIDS Soc2018;21:e25052 PMCID:PMC5978657

[201] Box GEP.Science and statistics..J Am Stat Assoc1976;71:791-9

[202] Wiktor SZ.Where next for hepatitis B and C surveillance?.J Viral Hepat2015;22:571-3

[203] Sixty-seventh World Health Assembly. Hepatitis. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf. [Last accessed on 28 Nov 2018]

[204] Lazarus JV,Safreed-Harmon K.Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014)..Hepatol Med Policy2016;1:3 PMCID:PMC5918699

[205] WHO. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Available from: www.measlesrubellainitiative.org/wp-content/uploads/2013/06/WHO-surveillance-standard.pdf. [Last accessed on 28 Nov 2018]

[206] Irving WL.Acute hepatitis C virus infection: a dynamic-and challenging-concept..J Infect Dis2010;202:1765-7

[207] Klevens RM,Vonderwahl C,Alelis K.Population-based surveillance for hepatitis C virus, United States, 2006-2007..Emerg Infect Dis2009;15:1499-502 PMCID:PMC2819847

[208] The National Academies Press. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C (2010). Available from: http://www.nap.edu/catalog/12793.html. [Last accessed on 28 Nov 2018]